OBJECTIVE: To compare the pregnancy rates (PRs) in intrauterine insemination (IUI) using recombinant FSH (rec-FSH) or highly purified urinary FSH (HP-FSH). DESIGN: Systematic review and metaanalysis. SETTING: University hospital. PATIENT(S): None. INTERVENTION(S): Electronic and manual searches. MAIN OUTCOME MEASURE(S): PR, per first cycle PR and per woman PR. RESULT(S): Six randomized trials (713 women, 1,581 cycles) were identified. In three the same doses of rec-FSH and HP-FSH were used ("equal dose" group), whereas in the other three the ratio HP-FSH:rec-FSH dose was 1.5. The global metaanalysis showed no differences in PRs. The PR per cycle was similar across the 1.5 ratio group (14.51% vs. 14.93%; relative risk [RR], 0.970; 95% confidence interval [CI], 0.687-1.369). However, the metaanalysis of the equal dose group, showed differences in the PR in favor of rec-FSH (16.36% vs. 12.31%; RR, 1.394; 95% CI, 1.004-1.936). Per woman PR analysis showed similar results (41.44% vs. 31.55%; RR, 1.273; 95% CI, 0.987-1.643). Per first cycle PR analysis showed a similar trend, although the difference did not reach significance (RR, 1.434; 95% CI, 0.934-2.203). CONCLUSION(S): Rec-FSH was associated with higher per cycle PR than HP-FSH, when used at the same dose, whereas the PR were similar when the dose of rec-FSH was 50% lower.
OBJECTIVE: To compare the pregnancy rates (PRs) in intrauterine insemination (IUI) using recombinant FSH (rec-FSH) or highly purified urinary FSH (HP-FSH). DESIGN: Systematic review and metaanalysis. SETTING: University hospital. PATIENT(S): None. INTERVENTION(S): Electronic and manual searches. MAIN OUTCOME MEASURE(S): PR, per first cycle PR and per woman PR. RESULT(S): Six randomized trials (713 women, 1,581 cycles) were identified. In three the same doses of rec-FSH and HP-FSH were used ("equal dose" group), whereas in the other three the ratio HP-FSH:rec-FSH dose was 1.5. The global metaanalysis showed no differences in PRs. The PR per cycle was similar across the 1.5 ratio group (14.51% vs. 14.93%; relative risk [RR], 0.970; 95% confidence interval [CI], 0.687-1.369). However, the metaanalysis of the equal dose group, showed differences in the PR in favor of rec-FSH (16.36% vs. 12.31%; RR, 1.394; 95% CI, 1.004-1.936). Per woman PR analysis showed similar results (41.44% vs. 31.55%; RR, 1.273; 95% CI, 0.987-1.643). Per first cycle PR analysis showed a similar trend, although the difference did not reach significance (RR, 1.434; 95% CI, 0.934-2.203). CONCLUSION(S): Rec-FSH was associated with higher per cycle PR than HP-FSH, when used at the same dose, whereas the PR were similar when the dose of rec-FSH was 50% lower.
Authors: Livia D Akl; Joao Batista A Oliveira; Claudia G Petersen; Ana L Mauri; Liliane F I Silva; Fabiana C Massaro; Ricardo L R Baruffi; Mario Cavagna; Jose G Franco Journal: Reprod Biol Endocrinol Date: 2011-08-23 Impact factor: 5.211
Authors: Angela Cánovas; Antonio Reverter; Kasey L DeAtley; Ryan L Ashley; Michelle L Colgrave; Marina R S Fortes; Alma Islas-Trejo; Sigrid Lehnert; Laercio Porto-Neto; Gonzalo Rincón; Gail A Silver; Warren M Snelling; Juan F Medrano; Milton G Thomas Journal: PLoS One Date: 2014-07-21 Impact factor: 3.240